Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Building a bright future

Building a bright future Herceptin while taking a buffeting over trading in the US, despite European growth contributing strongly to $2.96bn second quarter revenues. ... mission.”. It has manoeuvered into pole position to grab a significant slice of Roche’s $2bn-a-year

CHMP backs maintenance therapy for Tesaro's Zejula

CHMP backs maintenance therapy for Tesaro's Zejula The CHMP recommended approval of two biosimilars, namely Samsung Bioepis' Ontruzant (trastuzumab) - the first biosimilar of Roche's breast cancer therapy Herceptin to get a positive opinion in the EU - and

Amgen's Mvasi is first FDA-approved cancer biosimilar

Amgen's Mvasi is first FDA-approved cancer biosimilar At the ODAC meeting, the panel also backed approval of Mylan's biosimilar of Roche's breast cancer therapy Herceptin (trastuzumab) that, like Avastin, loses US patent protection in 2019.

Roche faces prospect of second Rituxan biosimilar in US

Roche faces prospect of second Rituxan biosimilar in US Rituxan is not the only one of Roche's big-selling biologic drugs to be under threat of biosimilar competition, with second and third top-sellers Herceptin (trastuzumab) and Avastin (bevacizumab)

Prix Galien opens for entries with new award

Prix Galien opens for entries with new award Previous UK Prix Galien winners include well-known brands such as Viagra, Herceptin, Glivec, Xolair, Bexero, Cervarix and Gardasil.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics